Hey all. I'm one of those lurkers on this board that hardly
Hey all. I'm one of those lurkers on this board that hardly ever posts but always keeps up with this board. Wanted to share something. My mom is a nurse manager at a Los Angeles County hospital affiliated with UCLA Medical Center. Because of this I've been telling my mom to reach out to Dr. Otto Yang or do whatever she can to try to get leronlimab at her hospital. We've both been invested in Cytodyn since 2016. Today she told me that she just so happened to walk into a room where there was an ongoing zoom meeting and she heard two doctors discussing leronlimab and the prospects of bringing it to the hospital. I was glad to hear this and I told her she's got to go bug these doctors to get them to bring it in! So the good news is that awareness of the drug is spreading. I'll keep you guys posted if there's any update.
While I'm here, I'll chime in my 2 cents. My first post on this board was to discuss what I thought was a big issue for this company - that they did nothing to spread awareness about the fact that the company even existed. Covid has been a blessing in this regard and I'm so glad everytime I hear that a new hospital is being added as a trial site. I have no knowledge about the medical industry but the way I see it is the fact that all these new hospitals/doctors now know about leronlimab, when they otherwise would not have if it weren't for covid, these hospitals/doctors can be used to help fill our cancer trials and other trials. If I was Nader I'd maintain all these new connections with these hospitals/doctors and when the times right have them help enroll our basket cancer, long hauler and other trials. How can a doctor say no to this drug once they're familiar with it?
GLTA
27
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Riding the Tactical Communication Wave Alright, here’s something to chew on over your morning coffee. The tactical communication market is projected to balloon from USD 13.14 billion in 2026 to a whopping USD 19.39 billion by 2031. That’s an 8.1% CAGR if you’re keeping track—no small peanuts. So what's driving this surge? It’s all about security, modernization,...
Continue Reading
Hexagon's Bold Move into Non-Destructive Testing Hexagon's latest play is turning heads in the measurement technology market. They've just wrapped up a strategic acquisition, snagging none other than Waygate Technologies from Baker Hughes. For those not familiar, Waygate's no small fry—this outfit's got a century-plus history in non-destructive testing (NDT) services....
Continue Reading
Deciding on Your Healthcare Anchor The quest for the perfect primary care provider isn't just routine; it's a cornerstone to your overall healthcare strategy. When Healthcare Services Expert Sheila A. Berschauer from Moses Lake Community Health lays it all out in HelloNation, she pinpoints selecting a provider as one of the mightiest decisions in your health journey. This...
Continue Reading
Pet Food Revolution? Wet Noses Takes the PLMA Stage Okay, listen up, pet lovers and industry folks alike—seems like Wet Noses, that Washington-based veteran in the dog treat game, is shaking up the pet food world. After cruising through the pet aisle for almost three decades, they're making a splash at the PLMA 2026. Why should we care? Well, they’re pushing this...
Continue Reading
When Halloween rolls around, you expect rabid kids clamoring for candy corn and chocolate bars. But this year, Idaho threw a spud into the sweets machine. Idaho's Potatoes Steal the Show In an unexpected twist, the Idaho Potato Commission ran a zany experiment on Halloween: kids had to choose between their beloved Halloween candy and a genuine Idaho potato. Imagine the...
Continue Reading
Virginia's Rising Innovation Ecosystem Virginia, a place you might not expect to hear much about in terms of innovation, is actually shaking things up and making waves on a national scale. Throwing their hat into the innovation arena, Virginia's landed itself a cozy #5 spot for its 'Innovation and Research Ecosystem,' according to Area Development's latest rankings. The...
Continue Reading
A Gourmet Transformation: Doughy's New Identity Cookie dough isn't just for sneaking off a spoon anymore, or at least that's what Doughy aims to redefine with its innovative new identity. Launched from Kelly Ramey's brainchild in her Santa Monica kitchen, Doughy's journey from a homemade recipe to a retail sensation is nothing short of remarkable. Love it or hate it, this...
Continue Reading
Just when you think the circus of energy utilities couldn't get any more outlandish, PG&E grabs the spotlight once more. Picture this: they've got the megaphone out, threatening to put the brakes on $2 billion in crucial infrastructure investments. Twenty-five thousand customers left hanging, just waiting for their lights to come on. As if that's not enough, PG&E is also...
Continue Reading
Decoding Wedding Attire: Suit vs. Tuxedo When it comes to wedding attire, it’s not just a simple choice between a suit or tuxedo. It’s a cascading series of choices that hinge on a myriad of factors; everything from the time of day, venue, and the level of formality to personal style tweaks can sway this decision. Listen up: Men’s clothing gurus Tom Napoli and Rico...
Continue Reading
FDA Throws Wrench Into Bright Minds' Plans This ain't the first time a biotech company's dream has hit the skids, but Bright Minds Biosciences (NASDAQ:DRUG) found themselves in the meat grinder when the FDA threw their epilepsy trial plans under the bus. The partial clinical hold wasn't a gentle slap on the wrist, but a gut punch driven by mouse toxicity findings and...
Continue Reading
s" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles